GlassScriptPhysician profile
Michael J Harwood
NPI 1083839138
$1,742.42
in general payments reported to CMS, 2019-2025
13 companies · $296 in 2025
The $296 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $192 · 2021: $117 · 2022: $190 · 2023: $452 · 2024: $291 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $959 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $958.93 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $903.38 | 2019-2025 | Tremfya, Stelara, Remicade |
| Abbvie INC. | $242.65 | 2019-2024 | |
| Lilly USA, LLC | $194.39 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $76.72 | 2020-2023 | Jublia |
| Leo Pharma INC. | $76.12 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $51.87 | 2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $49.39 | 2023 | |
| Sun Pharmaceutical Industries INC. | $38.79 | 2025 | |
| Novartis Pharmaceuticals Corporation | $34.47 | 2019-2020 | |
| Almirall LLC | $23.36 | 2020 | |
| Organon LLC | $19.08 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.67 | 2025 | Spevigo |
| Celgene Corporation | $13.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Harwood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.